BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 06, 2005
 |  BioCentury  |  Emerging Company Profile

Zelos: More bone, less risk

A young company looking to go head to head with a marketed pharma drug better have an appealing selling proposition. Zelos Therapeutics Inc. believes it has just that in its parathyroid hormone analog, which it says forms new bone without increasing the bone resorption associated with similar products. The company's injectable Ostabolin-C is in Phase II testing for osteoporosis.

Ostabolin-C was discovered by a research group at Canada's National Research Council that was studying cell signaling and bone metabolism.

CEO Duffy DuFresne said that by picking apart the parathyroid hormone (PTH) molecule, the group was able to better understand its activity and subsequently produce an analog with an improved therapeutic profile compared with other PTH analogs.

According to DuFresne, two characteristics distinguish Ostabolin-C (PTH

Read the full 613 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >